{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:50:36Z","timestamp":1793728236142,"version":"4.6.1"},"reference-count":120,"publisher":"Oxford University Press (OUP)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4,7]]},"DOI":"10.1093\/eurheartj\/ehs435","type":"journal-article","created":{"date-parts":[[2012,12,20]],"date-time":"2012-12-20T22:02:48Z","timestamp":1356040968000},"page":"1041-1049","source":"Crossref","is-referenced-by-count":140,"title":["Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?"],"prefix":"10.1093","volume":"34","author":[{"given":"Gregory Y.H.","family":"Lip","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,12,20]]},"reference":[{"key":"key\n\t\t\t\t20170626080356_EHS435C1","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/europace\/eus305","article-title":"2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation","volume":"14","author":"Camm","year":"2012","journal-title":"Europace"},{"key":"key\n\t\t\t\t20170626080356_EHS435C2","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1160\/TH11-07-0517","article-title":"Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options. Executive summary of the report from the 3rd AFNET\/EHRA Consensus Conference","volume":"106","author":"Kirchhof","year":"2011","journal-title":"Thromb Haemost"},{"issue":"Suppl 1","key":"key\n\t\t\t\t20170626080356_EHS435C3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1538-7836.2011.04302.x","article-title":"Stroke in atrial fibrillation: epidemiology and thromboprophylaxis","volume":"9","author":"Lip","year":"2011","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20170626080356_EHS435C4","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1253\/circj.CJ-12-1036","article-title":"Stroke and thromboembolism in atrial fibrillation","volume":"76","author":"Pisters","year":"2012","journal-title":"Circ J"},{"key":"key\n\t\t\t\t20170626080356_EHS435C5","first-page":"153","article-title":"Use of warfarin in non-rheumatic atrial fibrillation: a commentary from general practice","volume":"45","author":"Sweeney","year":"1995","journal-title":"Br J Gen Pract"},{"key":"key\n\t\t\t\t20170626080356_EHS435C6","doi-asserted-by":"crossref","first-page":"e531S","DOI":"10.1378\/chest.11-2304","article-title":"Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines","volume":"141","author":"You","year":"2012","journal-title":"Chest"},{"key":"key\n\t\t\t\t20170626080356_EHS435C7","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1212\/01.wnl.0000267275.68538.8d","article-title":"Independent predictors of stroke in patients with atrial fibrillation: a systematic review","volume":"69","author":"Stroke-in-AF-Working-Group","year":"2007","journal-title":"Neurology"},{"key":"key\n\t\t\t\t20170626080356_EHS435C8","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1160\/TH10-07-0491","article-title":"New-onset atrial fibrillation and warfarin initiation: high risk periods and implications for new antithrombotic drugs","volume":"104","author":"Garcia","year":"2010","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170626080356_EHS435C9","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jacc.2007.09.065","article-title":"Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation","volume":"51","author":"Fang","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170626080356_EHS435C10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1373\/clinchem.2007.096529","article-title":"Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve","volume":"54","author":"Cook","year":"2008","journal-title":"Clin Chem"},{"key":"key\n\t\t\t\t20170626080356_EHS435C11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/sim.4348","article-title":"Novel metrics for evaluating improvement in discrimination: net reclassification and integrated discrimination improvement for normal variables and nested models","volume":"31","author":"Pencina","year":"2012","journal-title":"Stat Med"},{"key":"key\n\t\t\t\t20170626080356_EHS435C12","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1160\/TH11-11-0768","article-title":"Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients","volume":"107","author":"Wilke","year":"2012","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170626080356_EHS435C13","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1093\/eurheartj\/ehl015","article-title":"Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on atrial fibrillation","volume":"27","author":"Nieuwlaat","year":"2006","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170626080356_EHS435C14","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1160\/TH09-08-0525","article-title":"A national survey of the management of atrial fibrillation with antithrombotic drugs in Italian primary care","volume":"103","author":"Mazzaglia","year":"2010","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170626080356_EHS435C15","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/europace\/eul097","article-title":"ACC\/AHA\/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: A report of the American College of Cardiology\/American Heart Association task force on practice guidelines and the European Society of Cardiology Committee for practice guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society","volume":"8","author":"Fuster","year":"2006","journal-title":"Europace"},{"key":"key\n\t\t\t\t20170626080356_EHS435C16","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170626080356_EHS435C17","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1052-3057(10)80159-4","article-title":"A differential effect of aspirin in prevention of stroke on atrial fibrillation. The stroke prevention in atrial fibrillation investigators","volume":"3","author":"SPAF-Investigators","year":"1993","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"key\n\t\t\t\t20170626080356_EHS435C18","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nrcardio.2011.112","article-title":"The role of aspirin for stroke prevention in atrial fibrillation","volume":"8","author":"Lip","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"key\n\t\t\t\t20170626080356_EHS435C19","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1161\/STROKEAHA.108.526988","article-title":"Effect of age on stroke prevention therapy in patients with atrial fibrillation: the Atrial Fibrillation Investigators","volume":"40","author":"van Walraven","year":"2009","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20170626080356_EHS435C20","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged study, BAFTA): a randomised controlled trial","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626080356_EHS435C21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/ageing\/afl129","article-title":"A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO)","volume":"36","author":"Rash","year":"2007","journal-title":"Age Ageing"},{"key":"key\n\t\t\t\t20170626080356_EHS435C22","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The Swedish Atrial Fibrillation cohort study","volume":"33","author":"Friberg","year":"2012","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170626080356_EHS435C23","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1160\/TH11-05-0364","article-title":"Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using a \u2018real world\u2019 nationwide cohort study","volume":"106","author":"Olesen","year":"2011","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170626080356_EHS435C24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1160\/TH09-05-0327","article-title":"New oral anticoagulant drugs in cardiovascular disease","volume":"104","author":"Ahrens","year":"2010","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170626080356_EHS435C25","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1136\/heartjnl-2012-301841","article-title":"New anticoagulant treatments to protect against stroke in atrial fibrillation","volume":"98","author":"Potpara","year":"2012","journal-title":"Heart"},{"key":"key\n\t\t\t\t20170626080356_EHS435C26","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626080356_EHS435C27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cjca.2012.01.021","article-title":"Focused 2012 update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: recommendations for stroke prevention and rate\/rhythm control","volume":"28","author":"Skanes","year":"2012","journal-title":"Can J Cardiol"},{"key":"key\n\t\t\t\t20170626080356_EHS435C28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2012.03.019","article-title":"Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation","author":"Lip","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170626080356_EHS435C29","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e7097","article-title":"Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis","author":"Rasmussen","year":"2012","journal-title":"Br Med J"},{"key":"key\n\t\t\t\t20170626080356_EHS435C30","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-155-10-201111150-00004","article-title":"Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the re-ly trial","volume":"155","author":"Oldgren","year":"2011","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170626080356_EHS435C31","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/S0140-6736(12)60986-6","article-title":"Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial","volume":"380","author":"Lopes","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626080356_EHS435C32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1161\/CIRCOUTCOMES.110.958108","article-title":"Moving the tipping point: The decision to anticoagulate patients with atrial fibrillation","volume":"4","author":"Eckman","year":"2011","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"key\n\t\t\t\t20170626080356_EHS435C33","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1160\/TH11-11-0784","article-title":"Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a \u2018real world\u2019 atrial fibrillation population: a modelling analysis based on a nationwide cohort study","volume":"107","author":"Banerjee","year":"2012","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170626080356_EHS435C34","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1160\/TH11-05-0353","article-title":"Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients","volume":"106","author":"Gallagher","year":"2011","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170626080356_EHS435C35","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCOUTCOMES.108.796185","article-title":"Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review","volume":"1","author":"Wan","year":"2008","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"key\n\t\t\t\t20170626080356_EHS435C36","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.jacc.2012.02.008","article-title":"New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC working group on thrombosis-task force on anticoagulants in heart disease position paper","volume":"59","author":"De Caterina","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170626080356_EHS435C37","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0140-6736(11)61294-4","article-title":"Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data","volume":"379","author":"Heneghan","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626080356_EHS435C38","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1160\/TH12-03-0151","article-title":"Effect of the vkorc1 d36y variant on warfarin dose requirement and pharmacogenetic dose prediction","volume":"108","author":"Kurnik","year":"2012","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170626080356_EHS435C39","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.amjmed.2009.11.025","article-title":"Underuse of oral anticoagulants in atrial fibrillation: a systematic review","volume":"123","author":"Ogilvie","year":"2010","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20170626080356_EHS435C40","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S0140-6736(10)61194-4","article-title":"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the re-ly trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626080356_EHS435C41","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626080356_EHS435C42","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170626080356_EHS435C43","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1161\/01.CIR.0000145172.55640.93","article-title":"Selecting patients with atrial fibrillation for anticoagulation: Stroke risk stratification in patients taking aspirin","volume":"110","author":"Gage","year":"2004","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170626080356_EHS435C44","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1160\/TH09-11-0757","article-title":"The CHADS2 score for stroke risk stratification in atrial fibrillation\u2014friend or foe?","volume":"104","author":"Karthikeyan","year":"2010","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170626080356_EHS435C45","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ahj.2008.03.010","article-title":"Chronic atrial fibrillation: incidence, prevalence, and prediction of stroke using the congestive heart failure, hypertension, age >75, diabetes mellitus, and prior stroke or transient ischemic attack (CHADS2) risk stratification scheme","volume":"156","author":"Rietbrock","year":"2008","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20170626080356_EHS435C46","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1160\/TH11-02-0061","article-title":"Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis","volume":"106","author":"Keogh","year":"2011","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170626080356_EHS435C47","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1160\/TH09-10-0746","article-title":"Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1","volume":"103","author":"Gorin","year":"2010","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170626080356_EHS435C48","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1161\/STROKEAHA.107.500199","article-title":"Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (active-w)","volume":"39","author":"Healey","year":"2008","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20170626080356_EHS435C49","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1540-8167.2009.01661.x","article-title":"The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1","volume":"21","author":"Lee","year":"2010","journal-title":"J Cardiovasc Electrophysiol"},{"key":"key\n\t\t\t\t20170626080356_EHS435C50","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1161\/CIR.0b013e318214876d","article-title":"2011 ACCF\/AHA\/HRS focused updates incorporated into the ACC\/AHA\/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines","volume":"123","author":"Fuster","year":"2011","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170626080356_EHS435C51","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1001\/archinte.158.12.1316","article-title":"Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials","volume":"158","author":"AF-Investigators","year":"1998","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20170626080356_EHS435C52","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0140-6736(01)05620-3","article-title":"Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening Study: a population based study","volume":"358","author":"Davies","year":"2001","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626080356_EHS435C53","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/eurjhf\/hfs005","article-title":"Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: The Loire Valley Atrial Fibrillation Project","volume":"14","author":"Banerjee","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t20170626080356_EHS435C54","article-title":"Impact of heart failure with normal ejection fraction on the occurrence of ischaemic stroke in patients with atrial fibrillation","author":"Jang","year":"2012","journal-title":"Heart"},{"key":"key\n\t\t\t\t20170626080356_EHS435C55","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/jhh.2011.105","article-title":"Hypertension and atrial fibrillation: epidemiology, pathophysiology and therapeutic implications","volume":"26","author":"Lau","year":"2012","journal-title":"J Hum Hypertens"},{"key":"key\n\t\t\t\t20170626080356_EHS435C56","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/eurheartj\/ehl504","article-title":"Effect of hypertension on anticoagulated patients with atrial fibrillation","volume":"28","author":"Lip","year":"2007","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170626080356_EHS435C57","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/jhh.2010.57","article-title":"Safety and efficacy of oral anticoagulation therapy in Chinese patients with concomitant atrial fibrillation and hypertension","volume":"25","author":"Ho","year":"2011","journal-title":"J Hum Hypertens"},{"key":"key\n\t\t\t\t20170626080356_EHS435C58","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1160\/TH12-03-0175","article-title":"The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study","volume":"107","author":"Olesen","year":"2012","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170626080356_EHS435C59","article-title":"The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy","author":"Coppens","year":"2012","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170626080356_EHS435C60","doi-asserted-by":"crossref","first-page":"d124","DOI":"10.1136\/bmj.d124","article-title":"Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study","volume":"342","author":"Olesen","year":"2011","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20170626080356_EHS435C61","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1160\/TH10-11-0692","article-title":"Ischaemic cardiovascular mortality in patients with non-valvular atrial fibrillation according to CHADS(2) score","volume":"105","author":"Kim","year":"2011","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170626080356_EHS435C62","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.atherosclerosis.2011.03.033","article-title":"Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation\u2014a nation wide database analysis","volume":"217","author":"Lin","year":"2011","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20170626080356_EHS435C63","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jama.290.8.1049","article-title":"A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: The Framingham Heart Study","volume":"290","author":"Wang","year":"2003","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170626080356_EHS435C64","doi-asserted-by":"crossref","first-page":"826.e13","DOI":"10.1016\/j.amjmed.2011.11.024","article-title":"Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study","volume":"125","author":"Olesen","year":"2012","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20170626080356_EHS435C65","doi-asserted-by":"crossref","first-page":"e3522","DOI":"10.1136\/bmj.e3522","article-title":"Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study","volume":"344","author":"Friberg","year":"2012","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20170626080356_EHS435C66","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/jama.2012.3490","article-title":"Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation","volume":"307","author":"Avgil Tsadok","year":"2012","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170626080356_EHS435C67","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/j.1538-7836.2012.04853.x","article-title":"Female sex as a risk factor for stroke in atrial fibrillation: A nationwide cohort study","volume":"10","author":"Mikkelsen","year":"2012","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20170626080356_EHS435C68","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1378\/chest.11-0862","article-title":"Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: The Loire Valley Atrial fibrillation project","volume":"141","author":"Olesen","year":"2012","journal-title":"Chest"},{"key":"key\n\t\t\t\t20170626080356_EHS435C69","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1161\/01.STR.0000236840.00467.84","article-title":"Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation","volume":"37","author":"Lip","year":"2006","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20170626080356_EHS435C70","author":"National-Collaborating-Centre-for-Chronic-Conditions","year":"2006"},{"key":"key\n\t\t\t\t20170626080356_EHS435C71","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"key\n\t\t\t\t20170626080356_EHS435C72","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1161\/STROKEAHA.110.590257","article-title":"Identifying patients at high risk for stroke despite anticoagulation. A comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort","volume":"41","author":"Lip","year":"2010","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20170626080356_EHS435C73","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1161\/STROKEAHA.110.609297","article-title":"Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal atrial fibrillation by continuous arrhythmia burden monitoring","volume":"42","author":"Boriani","year":"2011","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20170626080356_EHS435C74","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.amjmed.2009.12.013","article-title":"Improving stroke risk stratification in atrial fibrillation","volume":"123","author":"Lip","year":"2010","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20170626080356_EHS435C75","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1538-7836.2010.04085.x","article-title":"A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice","volume":"9","author":"Van Staa","year":"2011","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20170626080356_EHS435C76","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1161\/CIRCEP.111.966713","article-title":"Reliable identification of \u2018truly low\u2019 thromboembolic risk in patients initially diagnosed with \u2018lone\u2019 atrial fibrillation: The Belgrade Atrial Fibrillation study","volume":"5","author":"Potpara","year":"2012","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"key\n\t\t\t\t20170626080356_EHS435C77","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1016\/j.jacc.2011.08.045","article-title":"CHADS(2) and CHA(2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation","volume":"58","author":"Chao","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170626080356_EHS435C78","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm","year":"2010","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170626080356_EHS435C79","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0735-1097(98)00146-6","article-title":"Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke prevention in Atrial Fibrillation III Investigators","volume":"31","author":"Zabalgoitia","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170626080356_EHS435C80","doi-asserted-by":"crossref","first-page":"639","DOI":"10.7326\/0003-4819-128-8-199804150-00005","article-title":"Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The stroke prevention in Atrial Fibrillation Investigators Committee on Echocardiography","volume":"128","author":"SPAF-Investigators","year":"1998","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170626080356_EHS435C81","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(09)60040-4","article-title":"Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited","volume":"373","author":"Watson","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170626080356_EHS435C82","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1161\/01.CIR.0000077912.12202.FC","article-title":"Prognostic value of plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation","volume":"107","author":"Conway","year":"2003","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170626080356_EHS435C83","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1161\/01.CIR.0000033220.97592.9A","article-title":"Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors","volume":"106","author":"Conway","year":"2002","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170626080356_EHS435C84","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/01.mbc.0000114440.81125.bd","article-title":"D-dimer can predict survival in patients with chronic atrial fibrillation","volume":"15","author":"Mahe","year":"2004","journal-title":"Blood Coagul Fibrinolysis"},{"key":"key\n\t\t\t\t20170626080356_EHS435C85","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1160\/TH03-06-0363","article-title":"High d-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy","volume":"90","author":"Vene","year":"2003","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170626080356_EHS435C86","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/j.jacc.2009.12.049","article-title":"Evidence that d-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy","volume":"55","author":"Sadanaga","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170626080356_EHS435C87","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1161\/01.STR.0000260090.90508.3e","article-title":"High-sensitivity c-reactive protein and soluble cd40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis","volume":"38","author":"Lip","year":"2007","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20170626080356_EHS435C88","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1161\/CIRCULATIONAHA.111.038729","article-title":"Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (re-ly) substudy","volume":"125","author":"Hijazi","year":"2012","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170626080356_EHS435C89","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.jacc.2010.12.013","article-title":"Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk","volume":"57","author":"Marinigh","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170626080356_EHS435C90","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1161\/CIRCULATIONAHA.108.816082","article-title":"Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (atria) study","volume":"119","author":"Go","year":"2009","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170626080356_EHS435C91","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrneph.2012.160","article-title":"Anticoagulants in atrial fibrillation patients with chronic kidney disease","volume":"8","author":"Hart","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"key\n\t\t\t\t20170626080356_EHS435C92","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1105594","article-title":"Stroke and bleeding in atrial fibrillation with chronic kidney disease","volume":"367","author":"Olesen","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170626080356_EHS435C93","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/europace\/euq427","article-title":"Chronic renal disease and stroke in atrial fibrillation: balancing the prevention of thromboembolism and bleeding risk","volume":"13","author":"Lip","year":"2011","journal-title":"Europace"},{"key":"key\n\t\t\t\t20170626080356_EHS435C94","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.hrthm.2012.06.039","article-title":"Renal dysfunction and the risk of thromboembolic events in patients with atrial fibrillation after catheter ablation\u2014the potential role beyond the CHA(2)DS(2)-VASc score","volume":"9","author":"Chao","year":"2012","journal-title":"Heart Rhythm"},{"key":"key\n\t\t\t\t20170626080356_EHS435C95","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/europace\/eum191","article-title":"Outcome parameters for trials in atrial fibrillation: Recommendations from a Consensus Conference organized by the German Atrial Fibrillation Competence Network and the European Heart Rhythm Association","volume":"9","author":"Kirchhof","year":"2007","journal-title":"Europace"},{"key":"key\n\t\t\t\t20170626080356_EHS435C96","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1552-6569.2009.00440.x","article-title":"Cerebral microbleeds are uncommon in ischemic stroke associated with nonvalvular atrial fibrillation","volume":"21","author":"Chatzikonstantinou","year":"2011","journal-title":"J Neuroimaging"},{"key":"key\n\t\t\t\t20170626080356_EHS435C97","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1160\/TH11-10-0690","article-title":"Bleeding risk assessment and management in atrial fibrillation patients. Executive summary of a position document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] working group on thrombosis","volume":"106","author":"Lip","year":"2011","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170626080356_EHS435C98","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1161\/CIRCULATIONAHA.111.060061","article-title":"Use of the CHA2DS2-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation","volume":"126","author":"Lane","year":"2012","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170626080356_EHS435C99","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"key\n\t\t\t\t20170626080356_EHS435C100","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1111\/j.1538-7836.2011.04378.x","article-title":"Bleeding risk in \u2018real world\u2019 patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort","volume":"9","author":"Olesen","year":"2011","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20170626080356_EHS435C101","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/CIRCEP.111.967000","article-title":"Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events and mortality in anticoagulated patients with atrial fibrillation","volume":"5","author":"Gallego","year":"2012","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"key\n\t\t\t\t20170626080356_EHS435C102","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study","volume":"58","author":"Fang","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170626080356_EHS435C103","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jacc.2011.08.071","article-title":"The ATRIA risk scheme to predict warfarin-associated hemorrhage not ready for clinical use","volume":"59","author":"Olesen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170626080356_EHS435C104","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jacc.2012.06.019","article-title":"Performance of the Hemorr(2)hages, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: The AMADEUS (evaluating the use of sr34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) Study","volume":"60","author":"Apostolakis","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170626080356_EHS435C105","article-title":"A comparison of the HAS-BLED and ATRIA bleeding scores for predicting serious bleeding events in a \u2018real world\u2019 anticoagulated atrial fibrillation population","author":"Roldan","year":"2012","journal-title":"Chest"},{"key":"key\n\t\t\t\t20170626080356_EHS435C106","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1161\/CIRCEP.112.972869","article-title":"Assessing the risk of bleeding in patients with atrial fibrillation: The Loire Valley Atrial Fibrillation Project","volume":"5","author":"Lip","year":"2012","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"key\n\t\t\t\t20170626080356_EHS435C107","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1160\/TH11-12-0827","article-title":"The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the National Multicentre BNK Online Bridging Registry (BORDER)","volume":"108","author":"Omran","year":"2012","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170626080356_EHS435C108","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1161\/CIRCULATIONAHA.111.060061","article-title":"Use of the CHA2DS2-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in non-valvular atrial fibrillation","volume":"126","author":"Lane","year":"2012","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170626080356_EHS435C109","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1160\/TH11-04-0262","article-title":"Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective","volume":"106","author":"Faxon","year":"2011","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170626080356_EHS435C110","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1160\/TH11-08-0602","article-title":"Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe","volume":"106","author":"Huber","year":"2011","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170626080356_EHS435C111","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1160\/TH09-08-0580","article-title":"Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary intervention\/stenting","volume":"103","author":"Lip","year":"2010","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170626080356_EHS435C112","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs105","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"key\n\t\t\t\t20170626080356_EHS435C113","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1161\/CIRCULATIONAHA.111.055079","article-title":"Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish Atrial Fibrillation Cohort Study","volume":"125","author":"Friberg","year":"2012","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170626080356_EHS435C114","doi-asserted-by":"crossref","first-page":"297","DOI":"10.7326\/0003-4819-151-5-200909010-00003","article-title":"The net clinical benefit of warfarin anticoagulation in atrial fibrillation","volume":"151","author":"Singer","year":"2009","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170626080356_EHS435C115","doi-asserted-by":"crossref","first-page":"579","DOI":"10.7326\/0003-4819-155-9-201111010-00004","article-title":"Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable","volume":"155","author":"Connolly","year":"2011","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170626080356_EHS435C116","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1161\/01.STR.30.6.1223","article-title":"Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: Analysis of 2012 participants in the SPAF I\u2013III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators","volume":"30","author":"Hart","year":"1999","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20170626080356_EHS435C117","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1001\/archinte.1994.00420130036007","article-title":"Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials","volume":"154","author":"AF-Investigators","year":"1994","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20170626080356_EHS435C118","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/archinte.163.8.936","article-title":"A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin","volume":"163","author":"van Walraven","year":"2003","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20170626080356_EHS435C119","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cjca.2010.11.007","article-title":"Canadian Cardiovascular Society Atrial Fibrillation Guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter","volume":"27","author":"Cairns","year":"2011","journal-title":"Can J Cardiol"},{"issue":"Suppl 18","key":"key\n\t\t\t\t20170626080356_EHS435C120","first-page":"3","article-title":"RCPE UK consensus conference on \u2018approaching the comprehensive management of atrial fibrillation: evolution or revolution?","volume":"42","author":"Stott","year":"2012","journal-title":"J R Coll Physicians Edinb"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/34\/14\/1041\/17894443\/ehs435.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,7]],"date-time":"2019-07-07T07:38:59Z","timestamp":1562485139000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-lookup\/doi\/10.1093\/eurheartj\/ehs435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,20]]},"references-count":120,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2012,12,20]]},"published-print":{"date-parts":[[2013,4,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehs435","relation":{},"ISSN":["1522-9645","0195-668X"],"issn-type":[{"value":"1522-9645","type":"electronic"},{"value":"0195-668X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12,20]]}}}